Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain

被引：14

作者：

Becquemont, Laurent ^{[1
,16
]}

Delespierre, Tiba ^{[1
]}

Bauduceau, Bernard ^{[2
]}

Benattar-Zibi, Linda ^{[3
]}

Berrut, Gilles ^{[4
]}

Corruble, Emmanuelle ^{[5
]}

Danchin, Nicolas ^{[6
]}

Derumeaux, Genevieve ^{[7
]}

Doucet, Jean ^{[8
]}

Falissard, Bruno ^{[9
]}

Forette, Francoise ^{[10
]}

Hanon, Olivier ^{[11
]}

Pasquier, Florence ^{[12
]}

Pinget, Michel ^{[13
,14
]}

Ourabah, Rissane ^{[15
]}

Bucher, Sophie ^{[15
]}

Lazkani, Aida ^{[1
]}

Piedvache, Celine ^{[1
]}

Bertin, Philippe ^{[16
]}

机构：

[1] Univ Paris Sud, Hop Bicetre, AP HP, Pharmacol Dept,Fac Med Paris Sud, F-94275 Le Kremlin Bicetre, France

[2] Hop Begin, Dept Endocrinol, St Mande, France

[3] ORPEA CLINEA, Puteaux La Defense, France

[4] Univ Hosp Ctr, Nantes, France

[5] Univ Paris Sud, Bicetre Univ Hosp, AP HP, Fac Med Paris Sud,Dept Psychiat,INSERM,U669, F-94275 Le Kremlin Bicetre, France

[6] HEGP, Paris, France

[7] Hosp Civils Lyon, Louis Pradel Hosp, Bron, France

[8] Univ Rouen, St Julien Univ Hosp, Rouen, France

[9] Univ Paris Sud, Hop Paul Brousse, AP HP, Fac Med Paris Sud,INSERM,U669,Biostat Dept, F-94275 Le Kremlin Bicetre, France

[10] Univ Paris 05, Natl Fdn Gerontol, Paris, France

[11] Univ Paris 05, Hop Broca, AP HP, EA 4468,Geriatr Dept, Paris, France

[12] Univ Lille Nord France, Univ Hosp Ctr, UDSL, EA 1046, Lille, France

[13] Univ Strasbourg, Endocrinol Diabet & Dis Nutr Pole NUDE, Univ Hosp Strasbourg, Strasbourg, France

[14] Univ Strasbourg, European Ctr Study Diabet CeeD, Strasbourg, France

[15] Univ Paris Sud, Fac Med Paris Sud, Dept Gen Practice, F-94275 Le Kremlin Bicetre, France

[16] Hop Bicetre, Ctr Rech Clin, F-94275 Le Kremlin Bicetre, France

来源：

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY | 2014年 / 70卷 / 10期

关键词：

Dextropropoxyphene; Safety-based drug withdrawals; Chronic pain; Elderly patients; PATIENTS AGED 65; THERAPEUTIC MANAGEMENT;

D O I：

10.1007/s00228-014-1722-x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Describe the consequences of dextropropoxyphene (DXP) market withdrawal on analgesic prescriptions and on the quality of therapeutic management of chronic pain. From a cohort of non-institutionalised elderly patients with chronic pain recruited by general practitioners, we selected patients who were treated with DXP daily for at least 6 months just prior to DXP market withdrawal and who had an evaluation of pain and its impact on daily activities before and after DXP withdrawal. One hundred three patients took DXP daily for chronic pain. Immediately after DXP market withdrawal, 42 (40.8 %), 55 (53.4 %) and 3 (2.9 %) patients were treated with step 1, 2 and 3 analgesics, respectively, and 3 patients (2.9 %) were no longer receiving any analgesic medication. Among the 55 patients who continued on step 2 analgesics, 37 were treated with tramadol, 14 with codeine and 9 with opium. Pain intensity and the impact of pain on daily activities remained stable. DXP market withdrawal had no consequences on the intensity or impact of chronic pain in elderly patients.

引用

页码：1237 / 1242

页数：6

共 50 条

[1] Consequences of dextropropoxyphene market withdrawal in elderly patients with chronic pain
Laurent Becquemont
Tiba Delespierre
Bernard Bauduceau
Linda Benattar-Zibi
Gilles Berrut
Emmanuelle Corruble
Nicolas Danchin
Geneviève Derumeaux
Jean Doucet
Bruno Falissard
Francoise Forette
Olivier Hanon
Florence Pasquier
Michel Pinget
Rissane Ourabah
Sophie Bucher
Aida Lazkani
Celine Piedvache
Philippe Bertin
European Journal of Clinical Pharmacology, 2014, 70 : 1237 - 1242
[2] ANALGESIC EFFECT OF DEXTROPROPOXYPHENE HYDROCHLORIDE IN ELDERLY PATIENTS WITH CHRONIC PAIN SYNDROMES
BOYLE, RW
SOLOMONSON, CE
PETERSEN, JR
ANNALS OF INTERNAL MEDICINE, 1960, 52 (01) : 195 - 200
[3] Therapeutic Consequences of Dextropropoxyphene Withdrawal in France
Tamberou, Cheikh
Cornu, Catherine
Chretien, Emilie
Letrilliart, Laurent
Gueyffier, Francois
Laforest, Laurent
Chaissac, Elodie
Van Ganse, Eric
Aubrun, Frederic
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 284 - 284
[4] EMEA recommends market withdrawal of dextropropoxyphene products
Reactions Weekly, 2009, 1259 (1) : 3 - 3
[5] Consequences of Drugs Withdrawal: The Examples of Pioglitazone and Dextropropoxyphene in France
Pageot, Cecile
Bezin, Julien
Larrousse, Theo
Salvo, Francesco
Arnaud, Mickael
Haramburu, Francoise
Pariente, Antoine
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 546 - 547
[6] Effect of the market withdrawal of dextropropoxyphene on use of other prescribed analgesics
Reset, Askild
Skurtveit, Svetlana
Furu, Kari
Skovlund, Eva
SCANDINAVIAN JOURNAL OF PAIN, 2018, 18 (04) : 667 - 674
[7] A Survey on Forensic Cases Related to Dextropropoxyphene and Tramadol in the Context of the Withdrawal of Medicines Containing Dextropropoxyphene from the French Market
Castot, A.
Veyries, M. L.
Deveaux, M.
Pepin, G.
CLINICAL TOXICOLOGY, 2011, 49 (03) : 247 - 247
[8] Inadequate pain relief and consequences in oncological elderly patients
Caltagirone, Carlo
Spoletini, Ilaria
Gianni, Walter
Spalletta, Gianfranco
SURGICAL ONCOLOGY-OXFORD, 2010, 19 (03): : 178 - 183
[9] Management of the withdrawal of medicines containing dextropropoxyphene (DXP) and paracetamol (P) from the French Market
Castot, A.
Veyries, M.
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 98 - 98
[10] WITHDRAWAL OF ANGIOTENSIN ANTAGONISTS IN ELDERLY CHRONIC KIDNEY DISEASE PATIENTS
Petkov Stoyanov, V.
Jimenez Herrero, M. C.
Gutierrez Sanchez, M. J.
Martin Navarro, J. A.
JOURNAL OF HYPERTENSION, 2018, 36 : E289 - E290

← 1 2 3 4 5 →